A Network Pharmacology-Based Investigation into the Mechanism of Chebulagic Acid in the Treatment of Ulcerative Colitis

Yogesh Kumar

editor.probsci@gmail.com

Probecell Science

Open Access | E-ISSN: 3049-1584

Abstract View

A Network Pharmacology-Based Investigation into the Mechanism of Chebulagic Acid in the Treatment of Ulcerative Colitis

Author(s): Yogesh Kumar

Email(s): yogeshkumarsahu1222@gmail.com

Address:

School of Pharmacy, Rungta College of Pharmaceutical Sciences and Research, Rungta International Skills University, Kohka, Bhilai, - 490024, India

Published In: Volume - 3, Issue - 2, Year - 2026

DOI: Not Available

View HTML

View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Ulcerative colitis (UC) is character raised by changes in the immune system and the complete destruction of the intestinal mucosa. A long-term impact is inevitable. Terminalia chebulagic bioactive ellagitannin chebulagic acid (CA) may have anti-inflammatory or anti-free radical properties. Drugs for CA target and UC preventative measures were identified using network pharmacology. We have performed an analysis using Gene Ontology (GO), KEGG pathway enrichment, and proteins-protein link networks. Examining health and illness databases was the first step in the hunt for UC genes. The CA-UC contacts network contains a number of nodes associated with TNF, IL6, IL1B, PTGS2, NFKB1, and AKT1. Through its effects on the NF-κB, TNF, IL-17, MAPK, and PI3K-Akt receptors, enrichment testing demonstrates that CA influences inflammatory responses, cytokine signal ling, oxidative stress, and epithelial protection. New molecular docking experiments show that California interacts strongly with key inflammatory proteins. Among CA's several beneficial effects in UC include alterations to the immune system, an increase in natural inflammation, and the restoration of mucosal integrity. The molecular process provides an explanation for a treatment benefit. An inflammation-relieving polyphenol found in Terminalia, CA may help those suffering from ulcerative colitis. No one has a clue as to how it functions. Network pharmacology specialists looked at how CA affected UC. Predicted therapeutic targets were identical, according to protein-protein interaction networks, CA-UC gene matching, and enrichment analysis. A number of proteins are located within the CA-UC network. These include NFKB1, PTGS2, IL1B, IL6, and TNF. Research from the GO and KEGG databases indicates that CA has the potential to influence pathways like NF-κB, TNF, MAPK, and PI3K-Akt. Repair of the epithelium, responses to oxidative stress, immunological control, and inflammatory signal ling are all impacted by these pathways. Further research is necessary to confirm the therapeutic potential of CA for UC however it has the ability to decrease inflammation and mucosal dynamics.

Keywords:

Cite this article:
Kumar, Y. A Network Pharmacology-Based Investigation into the Mechanism of Chebulagic Acid in the Treatment of Ulcerative Colitis. Probecell Sci.,2026;3(2):1–14.

Reference

1. 1. Liao Z, Liu X, Li L, Li S, Xing X, Zheng X, et al. Mechanism of the Proprietary Chinese Medicine “JiuLiWan” to Treat Ulcerative Colitis Revealed by Network Pharmacology, Molecular Docking, and Experimental Verification In Vitro. ACS Omega. 2025 May 20;10(19):19598–613. doi:10.1021/acsomega.5c00261
2.        Liu M, Jiang Y, Yuan P, Li S, Zhang B, Zhou X, et al. Crystal engineering optimizes emodin-tetramethylpyrazine combination: From cocrystal design to in vivo anti-colitis efficacy assessment. Int J Pharm X. 2025 Dec;10:100436. doi:10.1016/j.ijpx.2025.100436
3.        Liu J, Zhang L, Wang Z, Chen S, Feng S, He Y, et al. Network Pharmacology-Based Strategy to Identify the Pharmacological Mechanisms of Pulsatilla Decoction against Crohn’s Disease. Front Pharmacol. 2022 Apr 5;13. doi:10.3389/fphar.2022.844685
4.        Liu Y, Shi F, Chen P, Sun J, Wang B, Liu Q. Using Network Pharmacology to Explore the Mechanism of Huanglian Jiedu Decoction in the Treatment of Ulcerative Colitis. Indian J Pharm Sci. 2023;85(S3). doi:10.36468/pharmaceutical-sciences.spl.674
5.        Shirvanyan A, Mirzoyan S, Trchounian K. Relationship between proton/ potassium fluxes and central carbon catabolic pathways in different Saccharomyces cerevisiae strains under osmotic stress conditions. Process Biochemistry. 2023 Oct;133:309–18. doi:10.1016/j.procbio.2023.09.015
6.        Jia L, Zhou H, Li W, Lv Z. Network Pharmacology Integrated Molecular Docking Revealed the Mechanism of Jianpi Yiqi Taohua Decoction Against Ulcerative Colitis. Medical Science Monitor. 2021 Nov 23;28. doi:10.12659/MSM.933537
7.        Lee A, Chung YC, Song KH, Ryuk JA, Ha H, Hwang YH. Network pharmacology-based identification of bioavailable anti-inflammatory agents from Psoralea corylifolia L. in an experimental colitis model. J Ethnopharmacol. 2023 Sep;313:116534. doi:10.1016/j.jep.2023.116534
8.        Zhu W, Zhang Z, Wang X. Network pharmacology analysis of Lanatoside C: molecular targets and mechanisms in the treatment of ulcerative colitis. Front Mol Biosci. 2025 Mar 21;12. doi:10.3389/fmolb.2025.1552360
9.        Gong B, Zhang C, Hu S, Zhang X, Zou H, Li J, et al. Network pharmacology and experimental verification in vivo reveal the mechanism of Zhushao Granules against ulcerative colitis. Biol Proced Online. 2025 Feb 14;27(1):7. doi:10.1186/s12575-025-00268-3
10.      Abhinand CS, Athira PA, Soumya SJ, Sudhakaran PR. Multiple Targets Directed Multiple Ligands: An In Silico and In Vitro Approach to Evaluating the Effect of Triphala on Angiogenesis. Biomolecules. 2020 Jan 23;10(2):177. doi:10.3390/biom10020177
11.      Yao G, Miao X, Wu M, Lv Z, Bai Y, Chang Y, et al. Pharmacokinetics of active compounds of a Terminalia chebula Retz. Ethanolic extract after oral administration rats using UPLC-MS/MS. Front Pharmacol. 2023 Jan 13;14. doi:10.3389/fphar.2023.1067089
12.      Sarkar A, Agarwal R, Bandyopadhyay B. Molecular docking studies of phytochemicals from Terminalia chebula for identification of potential multi-target inhibitors of SARS-CoV-2 proteins. J Ayurveda Integr Med. 2022 Apr;13(2):100557. doi:10.1016/j.jaim.2022.100557
13.      Elkhattabi L. Molecular docking analysis of PPARγ with phytochemicals from Moroccan medicinal plants. Bioinformation. 2023 Jul 31;19(7):795–805. doi:10.6026/97320630019795
14.      Hassan Bulbul MdR, Uddin Chowdhury MN, Naima TA, Sami SA, Imtiaj MdS, Huda N, et al. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon. 2022 Aug;8(8):e10220. doi:10.1016/j.heliyon.2022.e10220
15.      Shreevatsa B, Hegde S, Narayan P, Dharmashekar C, Jain A, Wani TA, et al. Targeting FAK, VEGF, and MTA1 proteins with Terminalia elliptica: a computational approach for anticancer activity. Front Oncol. 2024 Sep 17;14. doi:10.3389/fonc.2024.1427632
16.      Rajendran D, Easwaran N. In silico analysis of Triphala-derived polyphenols as inhibitors of TIR–TIR homodimerization in the inflammatory pathway. Frontiers in Bioinformatics. 2025 May 29;5. doi:10.3389/fbinf.2025.1565700
17.      Mukhopadhyay N, Shukla A, Makhal PN, Kaki VR. Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents. Heliyon. 2023 Mar;9(3):e14569. doi:10.1016/j.heliyon.2023.e14569
18.      Wei M, Li H, Li Q, Qiao Y, Ma Q, Xie R, et al. Based on Network Pharmacology to Explore the Molecular Targets and Mechanisms of Gegen Qinlian Decoction for the Treatment of Ulcerative Colitis. Biomed Res Int. 2020 Jan 25;2020(1). doi:10.1155/2020/5217405
19.      Cai T, Cai B. Network pharmacology and molecular docking reveal potential mechanism of esculetin in the treatment of ulcerative colitis. Medicine. 2023 Nov 10;102(45):e35852. doi:10.1097/MD.0000000000035852
20.      Fan W, Lan S, Yang Y, Liang J. Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of Huang–Qi–Gui–Zhi–Wu–Wu decoction against deep vein thrombosis. J Orthop Surg Res. 2023 Jun 30;18(1):475. doi:10.1186/s13018-023-03948-6
21.      Cao F, Cheng YS, Yu L, Xu YY, Wang Y. Bioinformatics Analysis of Differentially Expressed Genes and Protein–Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis. Medical Science Monitor. 2021 Jan 19;27. doi:10.12659/MSM.927917
22.      Maden SF, Acuner SE. Mapping Transcriptome Data to Protein–Protein Interaction Networks of Inflammatory Bowel Diseases Reveals Disease-Specific Subnetworks. Front Genet. 2021 Aug 18;12. doi:10.3389/fgene.2021.688447
23.      Wu Y, Liu X, Li G. Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis. Sci Rep. 2022 Jan 7;12(1):159. doi:10.1038/s41598-021-03980-8
24.      Wen Y, Li C, Huang P, Liu Z, He Y, Liu B. Transcriptional landscape of intestinal environment in DSS-induced ulcerative colitis mouse model. BMC Gastroenterol. 2024 Feb 2;24(1):60. doi:10.1186/s12876-024-03128-8
25.      Brooks-Warburton J, Modos D, Sudhakar P, Madgwick M, Thomas JP, Bohar B, et al. A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nat Commun. 2022 Apr 28;13(1):2299. doi:10.1038/s41467-022-29998-8
26.      Xu M, Kong Y, Chen N, Peng W, Zi R, Jiang M, et al. Identification of Immune-Related Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis. Front Immunol. 2022 Mar 22;13. doi:10.3389/fimmu.2022.855645
27.      Huang J, Zheng Y, Ma J, Ma J, Lu M, Ma X, et al. Exploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology. Gastroenterol Res Pract. 2021 Dec 21;2021:1–15. doi:10.1155/2021/4227668
28.      Han Y, Liu X, Dong H, Wen D. Screening of characteristic genes in ulcerative colitis by integrating gene expression profiles. BMC Gastroenterol. 2021 Dec 30;21(1):415. doi:10.1186/s12876-021-01940-0
29.      Zhang D, Yan P, Han T, Cheng X, Li J. Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis. PeerJ. 2021 Apr 27;9:e11321. doi:10.7717/peerj.11321
30.      Zhu L, Liang J. Network pharmacological prediction of the mechanism of action of Shen-Zhu-Lian-Bai Decoction in the treatment of ulcerative colitis. Sci Rep. 2024 Jun 20;14(1):14183. doi:10.1038/s41598-024-64683-4
31.      Huang Y, Wu Q, Li S, Lin X, Yang S, Zhu R, et al. Harnessing nature’s pharmacy: investigating natural compounds as novel therapeutics for ulcerative colitis. Front Pharmacol. 2024 Aug 14;15. doi:10.3389/fphar.2024.1394124
32.      Barberio B, Gracie DJ, Black CJ, Ford AC. Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis. Aliment Pharmacol Ther. 2025 Jul 23;62(1):4–21. doi:10.1111/apt.70209
33.      Derbak L, Bendif H, Ayad R, Rebbas K, Demirtas I, Yildiz I, et al. Extraction Process and Phenolic Profiling of Glebionis Coronaria: Insight into Antioxidant and Cytotoxic Activities with ADME-Based Therapeutic Potential. Food Anal Methods. 2025 Aug 24;18(8):1621–36. doi:10.1007/s12161-025-02818-7
34.      Kuo W, Odenwald MA, Turner JR, Zuo L. Tight junction proteins occludin and ZO‐1 as regulators of epithelial proliferation and survival. Ann N Y Acad Sci. 2022 Aug 17;1514(1):21–33. doi:10.1111/nyas.14798
35.      Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024 Mar 4;9(1):53. doi:10.1038/s41392-024-01757-9
36.      Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017 Jul 3;45(W1):W356–60. doi:10.1093/nar/gkx374

This journal is published under the Creative Commons Attribution (CC BY 4.0) License, permitting unrestricted use, distribution, and reproduction with appropriate credit to the original author(s).